Production (Stage)
Silence Therapeutics plc
SLNCF
$1.59
$0.6263.92%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.53M | 10.34M | -35.15M | -19.63M | -2.31M |
| Total Depreciation and Amortization | 138.00K | 149.80K | 149.70K | 150.10K | 152.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.59M | -11.36M | 8.78M | 568.90K | 3.34M |
| Change in Net Operating Assets | 10.49M | -26.76M | 638.90K | 12.84M | -10.32M |
| Cash from Operations | -12.31M | -27.62M | -25.58M | -6.07M | -9.14M |
| Capital Expenditure | -4.00K | -65.80K | -63.80K | -84.50K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.38M | 62.39M | -37.47M | 775.80K | -49.91M |
| Cash from Investing | -44.38M | 62.32M | -37.53M | 691.30K | -49.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 182.80K | -49.00K | -97.00K | -- |
| Issuance of Common Stock | 14.00K | -- | 6.34M | 944.00K | 133.02M |
| Repurchase of Common Stock | -- | -7.38M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 8.60M | -322.00K | 0.00 | -- |
| Cash from Financing | 14.00K | 1.40M | 7.77M | 1.07M | 133.02M |
| Foreign Exchange rate Adjustments | 232.00K | 6.53M | -6.51M | -195.50K | -35.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.44M | 42.62M | -61.85M | -4.51M | 73.93M |